drugset / Trial / NCT02883400

Spironolactone After Liver Transplant

NCT02883400

Phase 4 Completed 30 enrolled Wake Forest University Health Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.

Timeline

Start
2014-12
Primary completion
2018-01
Completion
2018-01

Publications

  • Background Russo MW, Krista Bossi, Gale Groseclose, Levi DM, Lon Eskind, Bennett Noell, Anderson WE, Zamor PJ, Vincent Casingal. Estimates of Glomerular filtration rate in liver transplant recipients are not accurate: A role for 24 hour urine creatinine clearance. Archives of Transplantation 2018:2:1-5.

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule 25 mg
Subject Spironolactone Small molecule 50 mg

Indications